Connect with us

News

Animal protein not linked to higher mortality risk, study finds

Published

on

Eating animal-sourced protein foods is not linked to a higher risk of death and may even offer protective benefits against cancer-related mortality, new research has found

The study analysed data from nearly 16,000 adults aged 19 and older using the National Health and Nutrition Examination Survey (NHAMES III).

Researchers examined how much animal and plant protein people typically consume and whether those patterns were associated with their risk of dying from heart disease, cancer or any cause.

They found no increased risk of death associated with higher intake of animal protein.

In fact, the data showed a modest but significant reduction in cancer-related mortality among those who ate more animal protein.

Stuart Phillips, Professor and Chair of the Department of Kinesiology at McMaster University, supervised the research.

He said: “There’s a lot of confusion around protein – how much to eat, what kind and what it means for long-term health.

“This study adds clarity, which is important for anyone trying to make informed, evidence-based decisions about what they eat.”

To ensure reliable results, the team employed advanced statistical methods, including the National Cancer Institute (NCI) method and multivariate Markov Chain Monte Carlo (MCMC) modelling, to estimate long-term dietary intake and minimize measurement error.

“It was imperative that our analysis used the most rigorous, gold standard methods to assess usual intake and mortality risk. These methods allowed us to account for fluctuations in daily protein intake and provide a more accurate picture of long-term eating habits,” said Phillips.

The researchers found no associations between total protein, animal protein or plant protein and risk of death from any cause, cardiovascular disease, or cancer.

When both plant and animal protein were included in the analysis, the results remained consistent, suggesting that plant protein has a minimal impact on cancer mortality, while animal protein may offer a small protective effect.

Observational studies like this one cannot prove cause and effect; however, they are valuable for identifying patterns and associations in large populations.

Combined with decades of clinical trial evidence, the findings support the inclusion of animal proteins as part of a healthy dietary pattern.

“When both observational data like this and clinical research are considered, it’s clear both animal and plant protein foods promote health and longevity,” said lead researcher Yanni Papanikolaou, MPH, president, Nutritional Strategies.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

News

AI can predict Alzheimer’s with almost 93% accuracy, researchers say

Published

on

Alzheimer’s AI can predict the disease with nearly 93 per cent accuracy using more than 800 brain scans, researchers say.

The system identified anatomical changes in the brain linked to the onset of the most common form of dementia, a condition that gradually damages memory and thinking.

The findings build on years of research suggesting AI could help spot early Alzheimer’s risk, predict disease and identify patients whose condition has not yet been diagnosed.

Benjamin Nephew, an assistant research professor at the Worcester Polytechnic Institute in Massachusetts, said: “Early diagnosis of Alzheimer’s disease can be difficult because symptoms can be mistaken for normal ageing.

“We found that machine-learning technologies, however, can analyse large amounts of data from scans to identify subtle changes and accurately predict Alzheimer’s disease and related cognitive states.”

The study used MRI scans, a type of detailed brain imaging, from 344 people aged 69 to 84.

The dataset included 281 scans showing normal mental function, 332 with mild cognitive impairment, an early stage of memory and thinking decline, and 202 with Alzheimer’s.

The scans covered 95 of the brain’s nearly 200 distinct regions and used an AI algorithm to predict patients’ health.

Being able to use AI to help diagnose Alzheimer’s earlier could give patients and doctors crucial time to prepare and potentially slow the progression of the disease.

The analysis showed that one of the top predictive factors was brain volume loss, or shrinkage, in the hippocampus, which helps form memories, the amygdala, which processes fear, and the entorhinal cortex, which helps provide a sense of time.

This pattern held across age and sex, with both men and women aged 69 to 76 showing volume loss in the right part of the hippocampus, suggesting it may be an important area for early diagnosis, the researchers noted.

However, the research also found that the way brain regions shrink differs by sex.

In females, volume loss occurred in the brain’s left middle temporal cortex, which is involved in language and visual perception. In males, it was mainly seen in the right entorhinal cortex

The researchers believe this could be linked to changes in sex hormones, including the loss of oestrogen in women and testosterone in men.

These conclusions could help improve methods of diagnosis and treatment going forward, Nephew said.

More than 7.2m Americans are living with Alzheimer’s, according to the Alzheimer’s Association.

More research is being done to reveal other impacting factors.

Nephew said: “The critical challenge in this research is to build a generalisable machine-learning model that captures the difference between healthy brains and brains from people with mild cognitive impairment or Alzheimer’s disease.”

Continue Reading

News

Vision implant firm raises US$230m

Published

on

A vision implant firm has raised US$230m as it seeks approval in Europe and the US for a device that restored sight in a small clinical trial.

The Alameda, California-based startup said the funding would support commercialisation of its Prima device.

It said an upcoming launch is planned in Europe and that it would become the first brain computer interface company to have a vision restoration device on the market.

A clinical trial in Europe found the small implant could work as artificial photoreceptors in the retina to restore functional central vision.

The implant is placed under the retina to replace the function of light-sensitive cells lost to disease. A special pair of glasses with an embedded camera and infrared projector sends light signals to the implant.

The study assessed the system in people with advanced dry age-related macular degeneration.

Of the 38 patients who received an implant, 32 were assessed at 12 months. Results showed the device led to a clinically meaningful improvement in visual acuity in 26 people.

The patients were able to read letters, numbers and words, according to the company.

Science Corporation said it has submitted a CE mark application to the European Union and applied to the US Food and Drug Administration for regulatory approval.

Darius Shahida, chief strategy officer, said: “Our imperative is to become the first BCI company to scale and achieve profitability.”

Founded in 2021, the company has now raised about US$490m in total. It said it is expanding its clinical trial programme to include other retinal diseases, such as Stargardt disease and retinitis pigmentosa.

The Series C round included existing investors Khosla Ventures, Lightspeed Venture Partners, Y Combinator, IQT and Quiet Capital.

Science Corporation said demand for the round exceeded its capital needs, with funds also earmarked for expanding research, manufacturing infrastructure and operations.

Continue Reading

News

Radiology AI may improve workflows

Published

on

Radiology AI may improve workflows and patient care, but the technology also brings challenges for radiology departments, research suggests.

A focus issue from the Journal of the American College of Radiology brings together invited research and reviews exploring how AI is being used across different practice types.

Barriers include insufficient infrastructure, strict institutional regulations and a lack of insurance reimbursement, all of which can hamper the integration of AI into routine clinical workflows.

Radiology, the branch of medicine that uses imaging such as X-rays and scans to diagnose and treat disease, is widely seen as one of the fields most likely to be reshaped by AI.

The research includes contributions arguing that workflow improvement is not simply a secondary benefit of AI, but a main determinant of whether a tool succeeds.

Gelareh Sadigh, associate editor for health services research at the Journal of the American College of Radiology, said: “When thoughtfully implemented, AI can complement human expertise and improve efficiency and patient care.

“Successful workflow optimisation requires the integration of AI technology into routine workflows.

“This can be hampered by insufficient infrastructure, strict institutional regulations, and lack of insurance reimbursement.

“Poor integration of AI may degrade workflows, satisfaction, and safety and perpetuate bias in healthcare.”

According to Dr Sadigh, the articles in the focus issue reflect a broader shift in radiology: workflow is not a secondary benefit of AI, but a key factor in whether a tool is successful.

If AI is going to meaningfully help radiology, it must make care delivery better and not more complicated.

Ruth C. Carlos, editor-in-chief of the Journal of the American College of Radiology, said: “This focus issue provides meaningful signposts for AI effectiveness as we navigate a rapidly shifting landscape.”

Continue Reading

Trending

Agetech World